Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia

Background and Objectives: BTK and BCL2 inhibitors have changed the treatment paradigms of high-risk and elderly patients with chronic lymphocytic leukemia (CLL), but their long-term efficacy and toxicity are still unknown and the costs are considerable. Our previous data showed that Rituximab (Rtx)...

Descripción completa

Detalles Bibliográficos
Autores principales: Pileckyte, Regina, Valceckiene, Vilma, Stoskus, Mindaugas, Matuzeviciene, Reda, Sejoniene, Jurgita, Zvirblis, Tadas, Griskevicius, Laimonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915691/
https://www.ncbi.nlm.nih.gov/pubmed/31671877
http://dx.doi.org/10.3390/medicina55110719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915691/
https://www.ncbi.nlm.nih.gov/pubmed/31671877
http://dx.doi.org/10.3390/medicina55110719

Ejemplares similares